Where Intra-Cellular Therapies Stands With Analysts
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has seen diverse analyst ratings over the last three months, with a positive shift in the average 12-month price target to $81.88, up 16.97% from $70. The company, focusing on drugs for central nervous system diseases, has shown a notable revenue growth of 75.05% as of September 30, 2023, but struggles with profitability and efficiency metrics. Analysts from firms like Needham, Mizuho, and Goldman Sachs have updated their ratings and price targets, reflecting optimism and caution.
February 23, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies has received varied analyst ratings, with a notable increase in the average 12-month price target to $81.88. The company's significant revenue growth contrasts with its profitability and efficiency challenges.
The positive shift in the average 12-month price target and the diverse analyst ratings indicate optimism about Intra-Cellular Therapies' future performance. However, the company's challenges in profitability and efficiency metrics may temper this optimism. The significant revenue growth is a strong positive signal, but investors should be cautious about the company's ability to translate this into net profits and efficient asset and equity management.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100